Sumatriptan-d6 (succinate)

• UNSPSC Description:

  Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research[1][2][3].

• Target Antigen:

  5-HT Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Field of Research:

  Neurological Disease

• Purity:

  99.63

• Solubility:

  H2O : 100 mg/mL (ultrasonic;warming)

• Smiles:

  OC(CCCC(CC(O)=O)C(O)=O.C(CN(C([2H])([2H])[2H])C([2H])([2H])[2H])C=1C=2C(NC1)=CC=C(CS(NC)(=O)=O)C2

• Molecular Weight:

  419.53

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]S J Peroutka, et al. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol. 1989 Apr 12;163(1):133-6. |[3]K L Dechant, et al. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992 May;43(5):776-98.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  1215621-31-0